Novo Nordisk said today that the FDA has delayed feedback on its much-anticipated diabetes drug Victoza (liraglutide) until the fourth quarter of this year. The company had predicted a positive response from the agency by this month. "Novo Nordisk continues the constructive dialog with the FDA regarding the regulatory process for liraglutide," the company said in a statement. Novo said the feedback delay will not impact company's financial results for 2009. The drug received EMEA approval in June and is already being marketed in Europe.
- take a look at Novo's release
- read the Reuters write-up